Related Experiment Video
Updated: Jun 7, 2026
10:52
Preparation of Mouse Pituitary Immunogen for the Induction of Experimental Autoimmune Hypophysitis
Published on: December 17, 2010
14.6K
Immune checkpoint inhibitor-associated new-onset hypophysitis: a retrospective analysis using the FAERS
Difei Lu1, Jun Yao1, Geheng Yuan1
1Department of Endocrinology, Peking University First Hospital, 100034, Beijing, P.R. China.
Endocrine
|July 4, 2024
Summary
Immune checkpoint inhibitor-associated hypophysitis (ICI-hypophysitis) is more common in males, particularly those on combination therapy. Older age and certain cancers indicate poor outcomes, while female sex and anti-CTLA-4 monotherapy are protective.
Area of Science:
- Oncology
- Immunology
- Endocrinology
Background:
- Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs), including hypophysitis.
- Understanding the prevalence and risk factors of ICI-hypophysitis is crucial for patient management.
Purpose of the Study:
- To investigate the prevalence and demographic characteristics of ICI-hypophysitis.
- To explore risk factors associated with the prognosis of ICI-hypophysitis.
Main Methods:
- Retrospective analysis of FAERS data for ICI-hypophysitis cases (2007-2022).
- Analysis of demographic data, co-occurring endocrinopathies, and clinical outcomes.
- Comparison between different immunotherapy subgroups.
Main Results:
- ICI-hypophysitis occurred in 1.46% of patients.
- Combination therapy and anti-CTLA-4 agents increased hypophysitis risk; males had higher reporting risk.
- Elder age, lung, and renal cancer were associated with severe outcomes.
- Female sex, anti-CTLA-4 monotherapy, and ICI-related diabetes were protective factors.
Conclusions:
- ICI-hypophysitis is a male-predominant irAE, often linked to anti-CTLA-4 therapy.
- Clinical awareness is vital for patients with risk factors like elder age or specific cancers.
- Female sex, anti-CTLA-4 monotherapy, and ICI-related diabetes correlate with better prognosis.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.